Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II study of STP705 for basal cell carcinoma (BCC). The open-label, dosage escalation trial showed 100% complete remission (CR) in the 180 μg dose cohort, with stable or improved cosmetic outcomes in all subjects. The treatment demonstrated a favorable safety profile, with no adverse events reported.
Study Details
The Phase II study evaluated STP705’s efficacy and safety in BCC patients. The 180 μg dose cohort achieved 100% CR, while subjects showed stable or better cosmetic results. The drug’s safety profile was favorable, with no cutaneous adverse reactions. The findings suggest STP705 could replace surgical treatments for BCC.
Future Plans
Sirnaomics plans to expand the study by adding experimental groups to assess STP705’s safety, tolerability, and efficacy via local injection at different doses. The final report is expected in Q1 2023.
Drug Profile
STP705, an anti-fibrosis siRNA, targets TGF-β1 and COX-2 genes using polypeptide nanoparticles (PNPs). The drug has orphan drug designations (ODDs) for cholangiocarcinoma and primary sclerosing cholangitis and is in trials for non-melanoma skin cancer, facial squamous cell carcinoma in situ (isSCC), and hypertrophic scarring.-Fineline Info & Tech
